NEWS
New Feature!!!! University Subject Rankings in 12 branches
FOR SCIENTIST REGISTRATION FOR INSTITUTIONAL BULK REGISTRATION
FOR EDIT YOUR UNIVERSITY / INSTITUTION PAGE
Some differences of the AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
List without CERN, Statistical Data etc. Only in AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
AD
Scientific Index 2024
About Us
Methodology
Compare & Choose
Contact - FAQ
login
Login
person_add
Register
school
University Rankings
subject
University Subject Rankings
place
Country Rankings
insights
i10 Productivity Rankings
insights
Subject Rankings
format_list_numbered
Top 100 Scientists
format_list_numbered
Citation Rankings
format_quote
Top 100 Institutions
local_fire_department
Country Top Lists
Andy I Chen
AD Scientific Index 2024
Medical and Health Sciences / Health Sciences
Oregon Health & Science University - Portland / United States
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Andy I Chen's MOST POPULAR ARTICLES
1-)
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'s lymphoma at risk of relapse or progression (AETHERA): a …CH Moskowitz, A Nademanee, T Masszi, E Agura, J Holowiecki, MH Abidi, ...The Lancet 385 (9980), 1853-1862, 20157222015
2-)
Ox40-ligand has a critical costimulatory role in dendritic cell: T cell interactionsAI Chen, AJ McAdam, JE Buhlmann, S Scott, ML Lupher Jr, EA Greenfield, ...Immunity 11 (6), 689-698, 19993811999
3-)
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNH Fowler, M Dickinson, M Dreyling, J Martinez-Lopez, A Kolstad, ...Nature medicine 28 (2), 325-332, 20222362022
4-)
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapseCH Moskowitz, J Walewski, A Nademanee, T Masszi, E Agura, ...Blood 132 (25), 2639-2642, 20182522018
5-)
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)F Morschhauser, IW Flinn, R Advani, LH Sehn, C Diefenbach, K Kolibaba, ...The Lancet Haematology 6 (5), e254-e265, 20192412019
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept